VJOncology is committed to improving our service to you

BTOG 2020 | NICE osimertinib rejection: UK patients

VJOncology is committed to improving our service to you

Tom Newsom-Davis

Tom Newsom-Davis, BSc, MBBS, PhD, FRCP, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK, talks on the rejection of osimertinib by NICE and the impact this may have on UK treatment outcomes, specifically patients with EGFR-mutant non-small cell lung cancer (NSCLC). This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress held in Dublin, UK.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter